HLS Therapeutics Inc.
HLS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 37.55% | 35.41% | 28.61% | 22.85% | 7.59% |
| Total Depreciation and Amortization | -19.40% | -24.99% | -28.87% | -27.55% | -20.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.41% | -41.43% | -40.10% | -37.81% | 7.51% |
| Change in Net Operating Assets | -30.13% | -35.96% | -77.35% | -45.75% | 168.94% |
| Cash from Operations | 3.67% | -14.18% | -49.31% | -45.22% | -13.66% |
| Capital Expenditure | -656.25% | 20.93% | 63.41% | 55.56% | 66.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -107.57% | 9,052.70% | 9,052.70% | 8,433.33% | 230.55% |
| Cash from Investing | -119.87% | 6,234.03% | 6,308.99% | 6,117.44% | 229.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -211.78% | -138.94% | -127.97% | -155.23% | -19.24% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | 43.41% | 70.14% | 61.34% | 10.74% | -80.28% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 100.00% | 100.00% |
| Other Financing Activities | 100.00% | 65.24% | 12.43% | 12.43% | -299.22% |
| Cash from Financing | -121.12% | -66.74% | -59.60% | -65.66% | -226.49% |
| Foreign Exchange rate Adjustments | 54.13% | -1,925.00% | -424.63% | 1,340.00% | -10.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -275.79% | 3.50% | -465.83% | -906.81% | 5,180.26% |